Table 1. Demographics of all patients who were evaluated for the expression of the 80 kDa fragment of e-cadherin in the serum.
| Cases | Mean | Median | Range | |
|---|---|---|---|---|
| Healthy volunteers (n=13) | ||||
| Age (years) | 13 | 26.3 | 27.0 | 22.0–32.0 |
| BPH (n=29) | ||||
| Age (years) | 63.6 | 63.0 | 60.0–68.0 | |
| Negative biopsies | 29 | |||
| Loc PCA | ||||
| Nonfailures/failures (n=109/n=21) | ||||
| Age (years) | 109/21 | 59.7/62.0 | 60.0/61.0 | 36.0–83.0/54.0–73.0 |
| PSA (ng ml−1) | 9.8/11.0 | 6.7/7.0 | 0.1–90.8/0.2–43.3 | |
| Gland weight (g) | 61.7/50.4 | 53.0/42.0 | 28.2–131/26.3–94.0 | |
| Follow-up (days) | 934.2/1659.6 | 867.0/1706.0 | 41–2226/171–2706 | |
| Tumour stage | ||||
| 1 | 14/1 | |||
| 2 | 74/2 | |||
| 3 | 12/8 | |||
| 4 | 8/7 | |||
| Gleason sum | ||||
| Unknown | 3/2 | |||
| 6 | 45/1 | |||
| 7 | 56/11 | |||
| 8 | 2/3 | |||
| 9 | 3/4 | |||
| Multifocality | ||||
| 0 | 26/4 | |||
| 1 | 83/17 | |||
| Extraprostatic extension | ||||
| 0 | 93/6 | |||
| 1 | 16/15 | |||
| Surgical margin | ||||
| 0 | 89/8 | |||
| 1 | 20/13 | |||
| Seminal vesicle involvement | ||||
| 0 | 101/14 | |||
| 1 | 8/7 | |||
| Met PCA (n=16) | ||||
| Age at diagnosis (years) | 16 | 65.2 | 68.0 | 57.0–79.0 |
| Months to death after diagnosis | 84.5 | 70.0 | 15.0–190.0 | |
| Gleason sum at diagnosis | ||||
| <6 | 3 | |||
| 7–8 | 9 | |||
| 9–10 | 4 | |||
BPH=benign prostatic hyperplasia; Loc PCA=localised prostate cancer; Met PCA=metastatic prostate cancer; PSA=prostate-specific antigen.